TISIDB

Summary
Symbol	AURKB
Name	aurora kinase B
Aliases	Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus. Chromosome. Chromosome, centromere. Cytoplasm, cytoskeleton, spindle. Midbody. Note=Localizes on chromosome arms and inner centromeres from prophase through metaphase and then transferring to the spindle midzone and midbody from anaphase through cytokinesis. Colocalized with gamma tubulin in the midbody. Proper localization of the active, Thr-232-phosphorylated form during metaphase may be dependent upon interaction with SPDYC. Colocalized with SIRT2 during cytokinesis with the midbody. Localization (and probably targeting of the CPC) to the inner centromere occurs predominantly in regions with overlapping mitosis-specific histone phosphorylations H3pT3 and H2ApT12.
Domain	PF00069 Protein kinase domain
Function	Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Involved in the bipolar attachment of spindle microtubules to kinetochores and is a key regulator for the onset of cytokinesis during mitosis. Required for central/midzone spindle assembly and cleavage furrow formation. Key component of the cytokinesis checkpoint, a process required to delay abscission to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage: phosphorylates CHMP4C, leading to retain abscission-competent VPS4 (VPS4A and/or VPS4B) at the midbody ring until abscission checkpoint signaling is terminated at late cytokinesis (PubMed:22422861, PubMed:24814515). AURKB phosphorylates the CPC complex subunits BIRC5/survivin, CDCA8/borealin and INCENP. Phosphorylation of INCENP leads to increased AURKB activity. Other known AURKB substrates involved in centromeric functions and mitosis are CENPA, DES/desmin, GPAF, KIF2C, NSUN2, RACGAP1, SEPT1, VIM/vimentin, HASPIN, and histone H3. A positive feedback loop involving HASPIN and AURKB contributes to localization of CPC to centromeres. Phosphorylation of VIM controls vimentin filament segregation in cytokinetic process, whereas histone H3 is phosphorylated at 'Ser-10' and 'Ser-28' during mitosis (H3S10ph and H3S28ph, respectively). A positive feedback between HASPIN and AURKB contributes to CPC localization. AURKB is also required for kinetochore localization of BUB1 and SGO1. Phosphorylation of p53/TP53 negatively regulates its transcriptional activity. Key regulator of active promoters in resting B- and T-lymphocytes: acts by mediating phosphorylation of H3S28ph at active promoters in resting B-cells, inhibiting RNF2/RING1B-mediated ubiquitination of histone H2A and enhancing binding and activity of the USP16 deubiquitinase at transcribed genes.

> Gene Ontology [ TOP ]
Biological Process	GO:0000022 mitotic spindle elongation GO:0000070 mitotic sister chromatid segregation GO:0000075 cell cycle checkpoint GO:0000226 microtubule cytoskeleton organization GO:0000723 telomere maintenance GO:0000819 sister chromatid segregation GO:0000910 cytokinesis GO:0001783 B cell apoptotic process GO:0002902 regulation of B cell apoptotic process GO:0002903 negative regulation of B cell apoptotic process GO:0006278 RNA-dependent DNA biosynthetic process GO:0007004 telomere maintenance via telomerase GO:0007051 spindle organization GO:0007052 mitotic spindle organization GO:0007059 chromosome segregation GO:0007062 sister chromatid cohesion GO:0007067 mitotic nuclear division GO:0007568 aging GO:0008608 attachment of spindle microtubules to kinetochore GO:0009314 response to radiation GO:0009411 response to UV GO:0009416 response to light stimulus GO:0009838 abscission GO:0010324 membrane invagination GO:0010498 proteasomal protein catabolic process GO:0010833 telomere maintenance via telomere lengthening GO:0010948 negative regulation of cell cycle process GO:0016233 telomere capping GO:0016570 histone modification GO:0016572 histone phosphorylation GO:0016925 protein sumoylation GO:0018105 peptidyl-serine phosphorylation GO:0018205 peptidyl-lysine modification GO:0018209 peptidyl-serine modification GO:0031145 anaphase-promoting complex-dependent catabolic process GO:0031577 spindle checkpoint GO:0032091 negative regulation of protein binding GO:0032200 telomere organization GO:0032204 regulation of telomere maintenance GO:0032206 positive regulation of telomere maintenance GO:0032210 regulation of telomere maintenance via telomerase GO:0032212 positive regulation of telomere maintenance via telomerase GO:0032465 regulation of cytokinesis GO:0032466 negative regulation of cytokinesis GO:0032467 positive regulation of cytokinesis GO:0032506 cytokinetic process GO:0032844 regulation of homeostatic process GO:0032846 positive regulation of homeostatic process GO:0033044 regulation of chromosome organization GO:0034501 protein localization to kinetochore GO:0034502 protein localization to chromosome GO:0034644 cellular response to UV GO:0035404 histone-serine phosphorylation GO:0036089 cleavage furrow formation GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic process GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043393 regulation of protein binding GO:0043988 histone H3-S28 phosphorylation GO:0045786 negative regulation of cell cycle GO:0045787 positive regulation of cell cycle GO:0046777 protein autophosphorylation GO:0051052 regulation of DNA metabolic process GO:0051054 positive regulation of DNA metabolic process GO:0051098 regulation of binding GO:0051100 negative regulation of binding GO:0051225 spindle assembly GO:0051231 spindle elongation GO:0051255 spindle midzone assembly GO:0051256 mitotic spindle midzone assembly GO:0051302 regulation of cell division GO:0051781 positive regulation of cell division GO:0051782 negative regulation of cell division GO:0051972 regulation of telomerase activity GO:0051973 positive regulation of telomerase activity GO:0051983 regulation of chromosome segregation GO:0060249 anatomical structure homeostasis GO:0061640 cytoskeleton-dependent cytokinesis GO:0070227 lymphocyte apoptotic process GO:0070228 regulation of lymphocyte apoptotic process GO:0070229 negative regulation of lymphocyte apoptotic process GO:0071214 cellular response to abiotic stimulus GO:0071459 protein localization to chromosome, centromeric region GO:0071478 cellular response to radiation GO:0071482 cellular response to light stimulus GO:0071887 leukocyte apoptotic process GO:0071897 DNA biosynthetic process GO:0072331 signal transduction by p53 class mediator GO:0090068 positive regulation of cell cycle process GO:0090307 mitotic spindle assembly GO:0098813 nuclear chromosome segregation GO:0099024 plasma membrane invagination GO:1901796 regulation of signal transduction by p53 class mediator GO:1902850 microtubule cytoskeleton organization involved in mitosis GO:1904353 regulation of telomere capping GO:1904355 positive regulation of telomere capping GO:1904356 regulation of telomere maintenance via telomere lengthening GO:1904358 positive regulation of telomere maintenance via telomere lengthening GO:2000106 regulation of leukocyte apoptotic process GO:2000107 negative regulation of leukocyte apoptotic process GO:2000278 regulation of DNA biosynthetic process GO:2000573 positive regulation of DNA biosynthetic process GO:2001252 positive regulation of chromosome organization
Molecular Function	GO:0004674 protein serine/threonine kinase activity GO:0004712 protein serine/threonine/tyrosine kinase activity GO:0035173 histone kinase activity GO:0035174 histone serine kinase activity
Cellular Component	GO:0000775 chromosome, centromeric region GO:0000776 kinetochore GO:0000779 condensed chromosome, centromeric region GO:0000780 condensed nuclear chromosome, centromeric region GO:0000793 condensed chromosome GO:0000794 condensed nuclear chromosome GO:0000922 spindle pole GO:0005813 centrosome GO:0005819 spindle GO:0005874 microtubule GO:0005875 microtubule associated complex GO:0005876 spindle microtubule GO:0010369 chromocenter GO:0030496 midbody GO:0031616 spindle pole centrosome GO:0032133 chromosome passenger complex GO:0044454 nuclear chromosome part GO:0045171 intercellular bridge GO:0051233 spindle midzone GO:0098687 chromosomal region

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-174143: APC/C-mediated degradation of cell cycle proteins R-HSA-174178: APC/C R-HSA-1640170: Cell Cycle R-HSA-69278: Cell Cycle, Mitotic R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-68886: M Phase R-HSA-392499: Metabolism of proteins R-HSA-68882: Mitotic Anaphase R-HSA-2555396: Mitotic Metaphase and Anaphase R-HSA-68877: Mitotic Prometaphase R-HSA-597592: Post-translational protein modification R-HSA-195258: RHO GTPase Effectors R-HSA-5663220: RHO GTPases Activate Formins R-HSA-5633007: Regulation of TP53 Activity R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation R-HSA-453276: Regulation of mitotic cell cycle R-HSA-2500257: Resolution of Sister Chromatid Cohesion R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins R-HSA-2990846: SUMOylation R-HSA-4615885: SUMOylation of DNA replication proteins R-HSA-2467813: Separation of Sister Chromatids R-HSA-162582: Signal Transduction R-HSA-194315: Signaling by Rho GTPases R-HSA-3700989: Transcriptional Regulation by TP53

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-174143: APC/C-mediated degradation of cell cycle proteins
R-HSA-174178: APC/C
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-68886: M Phase
R-HSA-392499: Metabolism of proteins
R-HSA-68882: Mitotic Anaphase
R-HSA-2555396: Mitotic Metaphase and Anaphase
R-HSA-68877: Mitotic Prometaphase
R-HSA-597592: Post-translational protein modification
R-HSA-195258: RHO GTPase Effectors
R-HSA-5663220: RHO GTPases Activate Formins
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation
R-HSA-453276: Regulation of mitotic cell cycle
R-HSA-2500257: Resolution of Sister Chromatid Cohesion
R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins
R-HSA-2990846: SUMOylation
R-HSA-4615885: SUMOylation of DNA replication proteins
R-HSA-2467813: Separation of Sister Chromatids
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
R-HSA-3700989: Transcriptional Regulation by TP53

Summary
Symbol	AURKB
Name	aurora kinase B
Aliases	Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between AURKB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	AURKB
Name	aurora kinase B
Aliases	Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of AURKB in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.61	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	Total # shRNA with >= 4-fold: 1	Resistant to T-cell proliferation
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	AURKB
Name	aurora kinase B
Aliases	Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of AURKB in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.528	0.227
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.764	0.678
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.369	0.815
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.868	0.127
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	1.165	0.365
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.506	0.786
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.23	0.553
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.533	0.646
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.213	0.853
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.669	0.516
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.973	0.518
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.551	9.06e-05

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of AURKB in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	2.7	1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	AURKB
Name	aurora kinase B
Aliases	Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AURKB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	AURKB
Name	aurora kinase B
Aliases	Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AURKB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AURKB. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	AURKB
Name	aurora kinase B
Aliases	Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AURKB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	AURKB
Name	aurora kinase B
Aliases	Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of AURKB expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	AURKB
Name	aurora kinase B
Aliases	Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between AURKB and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	AURKB
Name	aurora kinase B
Aliases	Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting AURKB collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting AURKB.

ID	Name	Drug Type	Targets	#Targets
DB04703	HESPERIDIN	Small Molecule	AURKB	1
DB05169	AT9283	Small Molecule	AURKA, AURKB	2
DB06486	Enzastaurin	Small Molecule	AKT1, AURKA, AURKB, CDK15, CHEK1, CHEK2, PIK3R1, PRKCB	8
DB07340	N~6~-cyclohexyl-N~2~-(4-morpholin-4-ylphenyl)-9H-purine-2,6-diamine	Small Molecule	AURKB, INCENP	2

Browse AURKB